Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of Directors
25 Enero 2024 - 3:15PM
Business Wire
Revvity, Inc. (NYSE: RVTY), today announced that Sophie
Vandebroek and Michael Klobuchar have been elected to its board of
directors, effective February 1, 2024.
“I am pleased to welcome Michael Klobuchar and Sophie Vandebroek
to Revvity’s board and look forward to their contributions as we
execute on our strategic vision,” said Alexis Michas, non-executive
chairman of the board. “Sophie brings deep acumen in AI, business
processes, sustainability, and cybersecurity, along with academic
advisory experience and leadership in global organizations. The
board will benefit from her long track record of innovation and
managing balanced research and development portfolios at large,
diverse and inclusive organizations. Mike joins our board with a
wealth of experience in developing and implementing strategic and
operational initiatives for complex global enterprises. His depth
and breadth of expertise across technical, operational, financial
roles — and his deep commitment to scientific innovation — will
provide the board with valuable insights to help propel Revvity
forward.”
“I would also like to thank Dr. Sylvie Gregoire for her guidance
serving on Revvity’s board since 2015, as she has decided not to
stand for re-election after she finishes her current term at our
annual shareholder meeting in April,” said Michas.
Dr. Vandebroek is the founder and owner of Strategic Vision
Ventures, an innovation consulting firm. Previously, she was
Massachusetts Institute of Technology’s Inaugural School of
Engineering Visiting Scholar. Until 2019 she was Vice President of
Emerging Technology Partnerships at IBM. Dr. Vandebroek also served
as the Chief Operating Officer of IBM Research. Prior to joining
IBM, she was Chief Technology Officer and President of the Xerox
Innovation Group. Dr. Vandebroek led Xerox’s global laboratories,
including PARC, Inc., where she was Chair of the board for eight
years. Earlier in her career, Dr. Vandebroek was Xerox’s Chief
Engineer and prior to that, VP of Xerox’s Canadian Research
Center.
She is also a member of the Board of Directors of IDEXX
Laboratories (IDXX), Inari Agriculture, and Wolters Kluwer N.V.
Previously Dr. Vandebroek served on the Board of Directors of
Analogic and Nypro Corporation. She holds 14 US patents and is a
Fellow of the Institute of Electrical & Electronics Engineers
(IEEE) and a Fellow of the Belgian-American Educational Foundation.
Dr. Vandebroek holds a bachelor’s and master’s degree in
electro-mechanical engineering from KU Leuven, Leuven, Belgium, and
a Ph.D in electrical engineering from Cornell University.
Mr. Klobuchar is Executive Vice President and Chief Strategy
Officer at Merck & Co. Inc. He is a member of Merck’s Executive
Committee, and has served in his current role since 2021,
overseeing the leadership, conception, planning and execution of
strategies to achieve Merck’s vision, mission and business
objectives. He is also responsible for setting and executing the
company’s global business development and M&A strategies as
well as leading the digital, data and IT infrastructure and
cybersecurity strategies. Mr. Klobuchar prioritizes and pursues
enterprise investment opportunities that modernize and expand the
company’s innovation pipeline and technology portfolio across
discovery, development, manufacturing and commercial. He has guided
the company through more than $25B in M&A activity over the
last three years.
Since joining Merck in 1998, Mr. Klobuchar has held positions of
increasing responsibility in research, manufacturing, commercial
planning, finance and strategy. Following the merger of Merck and
Shering-Plough, he led key elements in the integration of the
companies’ research operations. From 2019 to 2021, Mr. Klobuchar
was Senior Vice President, CFO and Head of Portfolio and Alliance
Management for Merck Research Laboratories, the company’s $13B
research and development organization. Mr. Klobuchar holds an MBA
from Villanova University, a master’s degree in chemical
engineering from Rutgers University and a bachelor’s degree from
Purdue University.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is
a call to action. Revvity provides health science solutions,
technologies, expertise and services that deliver complete
workflows from discovery to development, and diagnosis to cure.
Revvity is revolutionizing what’s possible in healthcare, with
specialized focus areas in translational multi-omics technologies,
biomarker identification, imaging, prediction, screening, detection
and diagnosis, informatics and more.
With 2022 revenue of more than $3 billion and over 11,000
employees, Revvity serves customers across pharmaceutical and
biotech, diagnostic labs, academia and governments. It is part of
the S&P 500 index and has customers in more than 190
countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube,
Facebook and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240125165583/en/
Investor Relations: Steve Willoughby
steve.willoughby@revvity.com
Media Relations: Chet Murray (781) 663-5719
chet.murray@revvity.com
Revvity (NYSE:RVTY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Revvity (NYSE:RVTY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024